IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole‐mount prostatectomy sections and implications for focal therapy

Prostate MRI is increasingly being used in men with a clinical suspicion of prostate cancer (PCa). However, development and validation of methods for focal therapy planning are still lagging.

[1]  Bing Ma,et al.  Challenges in accurate registration of 3-D medical imaging and histopathology in primary prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Johannes B Reitsma,et al.  STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration , 2016, BMJ Open.

[3]  S. Kaleci,et al.  Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score , 2017, BJU international.

[4]  François Cornud,et al.  Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging , 2011, BJU international.

[5]  J. Morote,et al.  Re: Lars Boesen, Nis Nørgaard, Vibeke Løgager, et al. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men. Eur Urol Oncol 2019;2:311-9. , 2020, European urology oncology.

[6]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[7]  Baris Turkbey,et al.  Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. , 2011, The Journal of urology.

[8]  Eveliina Arponen,et al.  Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT. , 2012, European journal of radiology.

[9]  A. Wong,et al.  A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer , 2015, International Urology and Nephrology.

[10]  T. H. van der Kwast,et al.  Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology. , 2018, European urology.

[11]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[12]  David J. Hawkes,et al.  Apparatus for Histological Validation of In Vivo and Ex Vivo Magnetic Resonance Imaging of the Human Prostate , 2017, Front. Oncol..

[13]  H. Merisaari,et al.  Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy , 2015, Journal of magnetic resonance imaging : JMRI.

[14]  Henry Rusinek,et al.  Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co‐registration software , 2014, BJU international.

[15]  D. Margolis,et al.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.

[16]  H. Merisaari,et al.  Evaluation of different mathematical models for diffusion‐weighted imaging of normal prostate and prostate cancer using high b‐values: A repeatability study , 2015, Magnetic resonance in medicine.

[17]  H. G. van der Poel,et al.  Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. , 2018, European urology.

[18]  A. Pelzer,et al.  Re: What Are We Missing? False-negative Cancers at Multiparametric MR Imaging of the Prostate. , 2017, European urology.

[19]  R. Shah,et al.  Recent advances in prostate cancer pathology: Gleason grading and beyond , 2016, Pathology international.

[20]  Shyam Natarajan,et al.  Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology , 2017, The Journal of urology.

[21]  I. Jambor.  Optimization of prostate MRI acquisition and post-processing protocol: a pictorial review with access to acquisition protocols , 2017, Acta radiologica open.

[22]  I. Balslev,et al.  Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men , 2018, JAMA network open.

[23]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[24]  T. H. van der Kwast.  Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology. , 2018, European urology.

[25]  Henry Rusinek,et al.  Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration Analysis. , 2015, The Journal of urology.

[26]  J. Fütterer,et al.  Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. , 2013, European urology.

[27]  Touradj Ebrahimi,et al.  MESH: measuring errors between surfaces using the Hausdorff distance , 2002, Proceedings. IEEE International Conference on Multimedia and Expo.

[28]  R. Shah,et al.  Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[29]  I. Balslev,et al.  Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men. , 2019, European urology oncology.

[30]  M. Schouten,et al.  ESUR prostate MR guidelines. Author reply. , 2013, European radiology.

[31]  John Kurhanewicz,et al.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer , 2012, BJU international.

[32]  P. Dean,et al.  Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial) , 2017, Journal of magnetic resonance imaging : JMRI.